-1768251243429.webp&w=3840&q=75)
2025 MaTOS Lung | Session VII | Small Cell Lung Cancer (SCLC)
Overview
Dr. Sheilds highlighted advances in SCLC care, including chemo-immunotherapy, emerging survival gains from key trials, evolving tumor origins, and the growing role of biomarkers for personalized treatment.
Dr. Bunn examined adenocarcinoma to SCLC transformation, often in EGFR-mutant tumors with p53/RB loss. Biopsies are key for diagnosis; outcomes are poor, highlighting need for new trials.
Dr. Iyenger reviewed advances in SCLC radiotherapy, stressing optimized thoracic dosing, limited role of consolidation, ongoing PCI debate, and trials combining radiation with immunotherapy.
Christine Hahn reviewed emerging SCLC therapies, highlighting durvalumab consolidation benefits, strong results with tarlatamab, promising ADCs, and novel targeted and bispecific agents.
Dr. Bunn examined adenocarcinoma to SCLC transformation, often in EGFR-mutant tumors with p53/RB loss. Biopsies are key for diagnosis; outcomes are poor, highlighting need for new trials.
Dr. Iyenger reviewed advances in SCLC radiotherapy, stressing optimized thoracic dosing, limited role of consolidation, ongoing PCI debate, and trials combining radiation with immunotherapy.
Christine Hahn reviewed emerging SCLC therapies, highlighting durvalumab consolidation benefits, strong results with tarlatamab, promising ADCs, and novel targeted and bispecific agents.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Paul A. Bunn, MD
Speakers and Panelists:
Misty Dawn Shields, MD, PhD
Paul A. Bunn, MD
Puneeth Iyengar, MD, PhD
Christine L. Hann, MD, PhD
Panelists:
Alberto Chiappori, MD
Nagla Abdel Karim, MD, PhD
Daniel Morgansztern, MD
Date of Release
January 8th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)